0:01 Hey everyone, it's nurse Sarah and in
0:03 this video I want to do a quick review
0:05 over the antibiotic class glyopeptides.
0:08 So let's get started. The glyopeptide
0:10 class actually doesn't have a common
0:12 prefix or suffix and a popular
0:14 medication in this class is vancoyasin.
0:16 Now whenever you look at this medication
0:18 don't get confused and think it's an
0:19 aminoglycide because remember that class
0:23 tends to end in mison like mycin n or m
0:26 i cin. However, this is not it. Look
0:28 more at this name a little bit. Look at
0:30 that co in there. Where else have you
0:33 seen co at? In its main class name,
0:36 glyco. So this is a glycoeptide.
0:39 Now what does it target? It targets gram
0:42 positive like MRSA and cedith. So what's
0:43 it going to treat? It's going to treat
0:46 those two along with bone infections,
0:49 pneumonia and endocarditis. So how does
0:51 it do this? Well, it works to inhibit
0:54 bacterial cell wall synthesis. So it has
0:56 a bacterial codle effect. Now to help
0:58 you remember the important concepts
1:00 about this class particularly
1:02 venkcomyosin I want you to remember the
1:05 word vanco. Venkcomiaosin is very toxic.
1:08 It has a narrow therapeutic range. So we
1:10 are going to draw trough levels. See
1:11 where our patients at. And you want to
1:13 draw the trough before the fourth dose
1:17 with a goal of it being about 10 to 20
1:19 micrograms per milliliter. Also, you
1:22 want to administer this very slowly IV
1:24 over more than 60 minutes because we
1:26 want to prevent a non-allergic reaction
1:27 and this is where the patient will start
1:30 to have flushing, rash, and hypotension.
1:33 It's also nephrotoxic. So, it can hurt
1:35 the kidneys. You want to monitor BUN and
1:38 creatin. Now, when VancO is being used
1:40 to treat CEDIFF, you want to remember
1:41 that you're going to be giving them the
1:43 oral form of this because that
1:45 medication is going to go in the GI
1:47 tract, which is where our bug is hanging
1:49 out. the IV form doesn't really treat
1:52 it. And then lastly, O for otoxicity.
1:54 It can harm the hearing. So monitor the
1:56 patient for ringing in the ears, hearing
1:58 loss, and vertigo. Okay, so that wraps
2:00 up this review. And if you'd like to
2:01 watch more videos in this series, you
2:03 can access the link in the description below.
Chrome Extension